Biomarin Pharmaceutical Inc.
0
0
0%

Financials

Income statement

Fundamentals currency is USD
Fiscal date 2024 2023 2022 2021
Total reported revenue 2.4B 2.4B 2.1B 1.8B
Cost of revenue 494.5M 514.9M 483.7M 470.5M
Gross profit 1.9B 1.9B 1.6B 1.4B
Operating expense
Research & development 636.8M 746.8M 649.6M 628.8M
Selling general and admin 859.9M 937.3M 854M 759.4M
Other operating expenses
Operating income 404.1M 158.1M 46.0M -74.3M
Non operating interest income
Income 63.8M 58.3M 18.0M 10.5M
Expense 10.5M 16.7M 15.4M 14.7M
Other income expense 4.5M -10.5M 101.6M 3.8M
Pretax income 461.7M 188.6M 149.6M -75.4M
Tax provision 97.9M 20.9M 8.0M -11.3M
Net income 363.8M 167.6M 141.6M -64.1M
Basic EPS 2.3 0.9 0.8 -0.4
Diluted EPS 2.2 0.9 0.8 -0.4
Basic average shares 162.0M 197.1M 192.8M 190.3M
Diluted average shares 162.0M 197.1M 192.8M 190.3M
EBITDA 545.9M 309.7M 163.3M 55.4M
Net income from continuing op. 363.8M 167.6M 141.6M -64.1M
Minority interests
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Main market

Exchange is currently active.
Closing in 4 hours 51 minutes

12:43
00:00
08:55
17:35
23:59

Trading Hours (Monday - Friday):

Pre-market
08:00 - 08:55
Main market
08:55 - 17:35
Post-market
17:35 - 17:50
All times are displayed in the Europe/Vienna timezone (CET, UTC+01:00).